Plant-Based Diets Lower Atherogenic Lipids in Established Cardiovascular Disease
A vegetarian or vegan diet can move the lipid panel in the right direction even after cardiovascular disease is already established. In a systematic review and meta-analysis of randomized controlled trials, these dietary patterns lowered total cholesterol and LDL cholesterol in adults with CVD, while leaving blood pressure and triglycerides unchanged. The signal was not broad across every cardiometabolic endpoint, but the lipid effects were consistent enough to matter clinically, especially for secondary prevention.
Six randomized controlled trials contributed data from 325 patients with cardiovascular disease. The pooled analysis compared vegetarian or vegan diets with omnivorous diets and focused on six prespecified outcomes: systolic blood pressure, diastolic blood pressure, total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides. The investigators used fixed- or random-effects models depending on heterogeneity, then examined subgroups to see whether intervention characteristics or patient factors influenced the results. That structure matters because dietary trials often vary in fat content, duration, age mix, and baseline body composition, all of which can blunt or magnify biochemical change.
The most clinically relevant finding was the reduction in atherogenic cholesterol fractions. Compared with omnivorous diets, vegetarian or vegan diets were associated with a mean reduction in total cholesterol of 0.63 mmol/L and a mean reduction in LDL cholesterol of 0.56 mmol/L. These are modest absolute shifts, but in secondary prevention even incremental LDL lowering can be meaningful when layered on top of statins, antiplatelet therapy, blood pressure control, and smoking cessation. In a patient who has already crossed the threshold into coronary, cerebrovascular, or peripheral vascular disease, dietary lipid lowering is not a cosmetic improvement. It is a biologically plausible extension of plaque stabilization.
One result complicates the simple enthusiasm around plant-based eating. HDL cholesterol fell slightly as well, with a mean reduction of 0.05 mmol/L. That decline was small, yet it is a reminder that lipid biology does not always move in one direction across every fraction. Plant-based diets can reduce saturated fat and dietary cholesterol while simultaneously altering total fat intake, fiber exposure, and hepatic lipoprotein handling. In practice, the fall in HDL should not be interpreted in isolation; the more important question is whether the net effect lowers apoB-containing particles and atherogenic burden. In this analysis, LDL and total cholesterol moved favorably, while triglycerides did not change significantly.
Blood pressure was another neutral outcome. No significant effect emerged for systolic or diastolic blood pressure, which suggests that the lipid benefit of vegetarian or vegan eating in established CVD does not automatically translate into hemodynamic improvement. The absence of a blood pressure signal may reflect the specific composition of the interventions, the limited sample size, or the fact that many patients with known CVD are already receiving antihypertensive therapy that leaves little room for dietary displacement. Triglycerides also remained unchanged, reinforcing that these diets may be better at modifying cholesterol fractions than broader metabolic risk markers in this population.
Why Low-Fat Vegan Patterns Appeared More Potent
Subgroup analyses pointed toward several modifiers of response. Low-fat vegan diets, intervention duration, age, and body mass index all influenced lipid outcomes. The strongest reductions in total cholesterol were seen in patients aged 60 years or younger and in those with BMI below 30. LDL cholesterol reductions were more pronounced in patients aged 60 years or younger and in those with BMI of 30 or higher. These patterns suggest that the same dietary intervention does not act uniformly across all patients with cardiovascular disease.
Low-fat vegan diets may work through a combination of lower saturated fat intake, lower dietary cholesterol, greater fiber exposure, and improved bile acid excretion. Each of those pathways can reduce hepatic cholesterol pools and drive LDL receptor activity, which helps clear circulating LDL particles. The effect is especially relevant in secondary prevention, where plaque burden is already present and the goal is to reduce further lipid deposition and inflammatory activation within the arterial wall. For clinicians, this supports a practical view of diet counseling: the quality of the plant-based pattern may matter as much as the label itself.
Age-related differences may reflect metabolic flexibility, background medication use, or dietary adherence. Younger patients may be more responsive to dietary change, while patients with higher BMI may show a more pronounced LDL response because of greater room for improvement in hepatic lipid handling and insulin-related metabolic pathways. The subgroup patterns do not prove causation, but they do suggest that a one-size-fits-all recommendation would miss clinically meaningful variation in response.
What This Means at the Bedside for Secondary Prevention
This meta-analysis supports vegetarian and vegan diets as a complementary strategy for lipid management in patients with established cardiovascular disease. The effect is not large enough to replace pharmacologic therapy, and the neutral findings for blood pressure and triglycerides limit any claim that plant-based eating alone can reset the full cardiometabolic profile. Even so, the reductions in total cholesterol and LDL cholesterol align with the central therapeutic target in secondary prevention: lowering atherogenic burden.
For patients already taking lipid-lowering medication, diet can still contribute. Small LDL reductions may improve the overall risk profile when combined with statins, ezetimibe, PCSK9 inhibition, and lifestyle measures such as exercise and smoking cessation. For patients who cannot tolerate higher-intensity drug therapy, dietary change may offer an additional, low-risk route to incremental benefit. The challenge is implementation, not theory. Adherence, nutritional adequacy, and long-term sustainability determine whether a plant-based intervention remains a short-lived experiment or becomes part of routine vascular risk reduction.
The review is also limited by scale. Only six randomized trials and 325 patients were available, which leaves uncertainty around durability, generalizability, and effect size across diverse cardiovascular phenotypes. The outcomes were biochemical rather than hard clinical events, so the analysis cannot establish whether these lipid changes reduce myocardial infarction, stroke, hospitalization, or mortality. The PROSPERO registration number, CRD420261283606, signals a prespecified approach, but the underlying evidence base remains relatively small for a question with major preventive implications.
Even with those limits, the clinical message is coherent: vegetarian and vegan diets, particularly low-fat vegan patterns, can improve atherogenic lipids in patients with cardiovascular disease. The signal is strongest for LDL cholesterol and total cholesterol, and weakest for blood pressure, triglycerides, and HDL cholesterol. Future trial data will need to determine whether these biochemical gains translate into fewer recurrent cardiovascular events in real-world secondary prevention.